BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34263138)

  • 1. Updates on the understanding and management of thyroid eye disease.
    Men CJ; Kossler AL; Wester ST
    Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
    Neumann S; Krieger CC; Gershengorn MC
    Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.
    Wang Y; Patel A; Douglas RS
    Ther Clin Risk Manag; 2019; 15():1305-1318. PubMed ID: 31814726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Novel Medical Treatments for Thyroid Eye Disease.
    Park JW; Yoon JS
    Korean J Ophthalmol; 2024 May; ():. PubMed ID: 38773958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
    Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid eye disease: From pathogenesis to targeted therapies.
    Yoon JS; Kikkawa DO
    Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
    Yu CY; Ford RL; Wester ST; Shriver EM
    Indian J Ophthalmol; 2022 Jul; 70(7):2335-2345. PubMed ID: 35791115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
    Smith TJ
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.